Aleniglipron (GSBR-1290) Tracker
Track the oral GLP-1 race — and your protocol today
Aleniglipron (formerly GSBR-1290) is Structure Therapeutics’ once-daily oral small-molecule GLP-1 receptor agonist, advancing through clinical trials as a pill alternative to injections. It is investigational and not FDA approved. Shotlee is the free app to track your current protocol while the oral GLP-1 field develops.
What is aleniglipron (GSBR-1290)?
Aleniglipron (GSBR-1290) is a once-daily oral small-molecule GLP-1 receptor agonist from Structure Therapeutics. Unlike peptide GLP-1 drugs that require injection or strict dosing rules, small-molecule oral agonists aim to deliver GLP-1 weight loss in a simple daily tablet.
It is one of several oral GLP-1 candidates racing toward market alongside Lilly’s orforglipron (Foundayo), Roche’s CT-996, and AstraZeneca’s AZD5004. Aleniglipron has reported encouraging early-phase weight loss and is advancing into later-stage trials.
Aleniglipron Key Facts
What to Track in Shotlee
Build clean baseline data now so you can compare if oral GLP-1s reach the market.
Oral GLP-1 Development Outlook
Protocol FAQs
Aleniglipron (formerly GSBR-1290) is Structure Therapeutics’ once-daily oral small-molecule GLP-1 receptor agonist in clinical development for weight loss and type 2 diabetes. It is investigational and not FDA approved.
Yes. GSBR-1290 is the development code and aleniglipron is the proposed nonproprietary name for the same Structure Therapeutics oral GLP-1.
Both are once-daily oral small-molecule GLP-1 agonists, but they are different molecules from different companies (Structure Therapeutics vs Eli Lilly). They are competing candidates in the oral GLP-1 race; head-to-head data does not exist.
It is investigational and only available in trials. Timing depends on later-stage results and regulatory review. Follow Shotlee’s tracker pages for updates.
Yes. Shotlee logs doses, weight, side effects, and labs for your current medication for free, so you have a clean baseline if oral GLP-1s like aleniglipron launch.
Track Your Protocol in Shotlee
Free dose logs, weight trends, and side effect tracking — ready for the oral GLP-1 wave.